Aroa Biosurgery Limited (ARX) is currently Undervalued by 65.54%

Aroa Biosurgery Limited (ARX) appears undervalued by approximately 65.54% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.

Upside (live) 65.54% (from live valuation API)
Confidence (live) 9.5/10 (Very High)

Confidence Score is based on the magnitude of upside or downside vs intrinsic value.

Fair value estimate

Unlock fair value

Current price

$13.25

Stock valuation checker

Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.

Explore Our Valuation Calculators

Intrinsic Value Calculator (DCF)ROE Calculator Stock Valuation Calculator

Why is Aroa Biosurgery Limited overvalued or undervalued?

Intrinsic value work anchors Aroa Biosurgery Limited on owner earnings and balance-sheet capacity; the current quote trades below that anchor, which frames the stock as relatively cheap on a fundamentals-first view.

Versus historical valuation bands, ARX is closer to the lower end of where this business has traded when profitability and growth were comparable—useful context before reading any single headline multiple.

Forward market expectations are muted: the price does not require heroic assumptions to converge with our fair-value zone, but sector peers and macro rates still deserve a quick sanity check on the company page.

Key metrics

P/E ratio: 36.2x
Revenue growth (TTM y/y): 15%
Profit margin: 33.2%
Fair value (model): Unlock

Next steps

Frequently asked questions — ARX

Is ARX overvalued right now?

A stock is overvalued when its market price sits above a reasonable fair value range. Use the live snapshot on this page for ARX, then validate with fundamentals and peer multiples.

What is Aroa Biosurgery Limited's intrinsic value?

Our DCF, P/E Multiple, and P/S Multiple models estimate whether ARX trades above or below fair value. At $13.25, Aroa Biosurgery Limited currently looks undervalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.

How is Aroa Biosurgery Limited's intrinsic value calculated?

Tickerplace calculates ARX's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.

Is ARX undervalued right now?

Based on our 2026 valuation models, Aroa Biosurgery Limited (ARX) appears undervalued at $13.25 with about 65.5% upside to fair value. Treat this as a screen—verify fundamentals on the company profile.

Peers for ARX: open their overvalued / undervalued view.

Instant valuation answer